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Hepatocellular carcinoma (HCC) is the third largest cause of cancer deaths worldwide. The role of molecular changes in HCC
have been used to identify prognostic markers and chemopreventive or therapeutic targets. It seems that toll-like receptors (TLRs)
as well as the nuclear factor (NF)-κB, and JNK pathways are critical regulators for the production of the cytokines associated
with tumor promotion. The cross-talk between an inﬂammatory cell and a neoplastic cell, which is instigated by the activation
of NF-κB and JNKs, is critical for tumor organization. JNKs also regulate cell proliferation and act as oncogenes, making them
the main tumor-promoting protein kinases. TLRs play roles in cytokine and hepatomitogen expression mainly in myeloid cells
and may promote liver tumorigenesis. A better understanding of these signaling pathways in the liver will help us understand the
mechanism of hepatocarcinogenesis and provide a new therapeutic target for HCC.
1.Introduction
Hepatocellular carcinoma (HCC) is the third largest cause of
cancer deaths worldwide, particularly in Africa and Eastern
Asia. Major HCC risk factors include infection with hepatitis
B (HBV) or C viruses (HCV) and cirrhosis associated
with chronic inﬂammation. The fungal contaminant aﬂa-
toxin B1 and environmental pollutants, such as aromatic
amines, vinyl chloride, polycyclic aromatic hydrocarbons,
and nitrosamines are also risk factors [1].
The role of molecular changes in the acquisition of
resistance or susceptibility to HCC and the importance of
genetically susceptible and resistant murine models have
been used to identify prognostic markers and chemopreven-
tive or therapeutic targets. Studies with genetically modiﬁed
micehaverevealedmanygenesassociatedwithHCC.Among
them, we focus on toll-like receptors (TLRs) as well as
the nuclear factor (NF)-κB and the JNK pathways in HCC
development in this paper.
2. PutativeMechanisms of HCC Development
Although many putative causal factors are involved in the
development of HCC, carcinogenic mechanisms have been
diﬃcult to elucidate. Among them, particular HBV or HCV
proteins induce HCC without other oncogenic alterations
in mouse models [2]. It is thought that chronic liver injury
resulting in compensatory proliferation of diﬀerentiated
hepatocytes is one of the major pathogenic mechanisms
underlying HCC development [3, 4]. Several signal trans-
d u c t i o np a t h w a y ss u c ha sN F - κB and JNK are involved in the
pathogenesisoftheseviruses.Forexample,theHCVcoreand
HBx proteins are the most potent signal inducers for NF-κB
and AP-1 [5].
Another important etiology of HCC development is
obesity-induced hepatosteatosis, which includes more severe
complications such as nonalcoholic steatohepatitis (NASH),
classiﬁed as nonalcoholic fatty liver disease (NAFLD) [6].
Several mechanisms have been proposed to explain how
NASH increases HCC risk, including the prevalence of
insulin resistance among obese individuals, which results in
elevated circulating concentrations of insulin and insulin-
like growth factor 1 (IGF-1) [7] and a low-grade inﬂamma-
tory response with elevated production of cytokines, such as
TNF and IL-6 [8]. In these cases, it seems that the NF-κBa n d
JNKpathwaysarecriticalregulatorsfortheproductionofthe
cytokines associated with tumor promotion.2 Gastroenterology Research and Practice
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3. NF-κBa n dH C C
3.1. NF-κB Signaling Pathway. NF-κB transcription factors
are key regulators of innate and adaptive immune responses,
inﬂammation, and cell survival [9]. Many proinﬂammatory
stimuli activate NF-κB, mainly via IκB kinase-(IKK) depen-
dent phosphorylation and degradation of the κB inhibitor
(IκB) proteins. Five members, p65 (RelA), p50/NF-κB1, c-
Rel,RelB,andp52/NF-κB2,belongtothemammalianNF-κB
family and are assembled by dimerization. Once activated,
NF-κB dimers stimulate transcription of genes encoding
cytokines and antiapoptotic factors [10]. IKK consists of
two catalytic subunits, IKKα and IKKβ, and a regulatory
component, NEMO/IKKγ. IKK activation occurs primarily
through IKKβ [10], whose absence increases susceptibility
to tumor necrosis factor-α-(TNFα-) induced apoptosis [11]
(Figure 1).
Inthenonclassicalpathway,NF-κBacti vationistrigger ed
by members of the TNF family, including B-cell-activating
factor, which belongs to the TNF family (BAFF), the CD40
ligand, and lymphotoxin β/LTβ. Dimerized IKKα is activated
by NF-κB-inducing kinase (NIK), after which the p100
proteins are processed. After processing p100, p52/NF-κB2
complexes move into the nucleus, resulting in the expression
of genes that activate the adaptive immune response and the
development of secondary lymphoid organs [12]( Figure 1).
3.2. NF-κB Activation and Carcinogenesis. Tumor initiation
means cellular immortality, which happens through DNA
mutation, but the relationship with NF-κB activation has
not been considered in detail for this process. However, the
ﬁrst clue linking NF-κB to cancer was recognizing that c-
rel, which is a v-rel oncogene cellular homologue, encodes
an NF-κB subunit and that all of these proteins share the
Rel homology DNA-binding domain [13]. Not surprisingly,
overexpression of normal Rel proteins promotes oncogenic
transformation.
Participation of NF-κB activation in the carcinogenic
promotion and progression stages has become clear in recent
years. This promotion stage is the cell proliferative stage,
and proliferation, antiapoptosis, angiogenesis, invasion, and
metastasis become important [14].
It is unclear whether NF-κB activation is directly associ-
ated with tumor cell proliferation. There are a few reports
of a strong participation in transcriptional regulation ofGastroenterology Research and Practice 3
the expression of growth factors through NF-κB activation.
However, for the activation and inﬁltration of inﬂammatory
cells, inhibition of NF-κB activation may reduce expression
of these growth factors. TNFα,w h i c hi sas t r o n gN F -
κB-activating factor whose expression is regulated by NF-
κB, is produced by macrophages due to inﬂammation and
plays a central role in inﬂammation but has also been
suggested as an accelerator factor of cell proliferation [15].
In addition, the possibility that NF-κBa c t i v a t i o no p e r a t e s
on cell growth through cyclin expression is indicated in
certain cell types [16]. In contrast, Ikkβ deletion accelerates
hepatocyte growth. Ikkβ-deﬁcient hepatocyte proliferative
responses show heightened sensitivity to TGF-α [17], sug-
gesting that involvement of NF-κBa c t i v a t i o ni np r o l i f e ra t i o n
diﬀers among cell types.
Antiapoptosis is also important for maintaining cancer
cells. A large number of antiapoptotic factors, such as cIAPs,
c-FLIP, and BclX, are controlled by NF-κBa c t i v a t i o n[ 18].
Tumor cells with constitutive NF-κBa c t i v a t i o na r eh i g h l y
resistant to anticancer drugs, and the inhibition of NF-κB
activity in those cells increases tumor sensitivity to these
therapies [19–22].
Invasion and metastasis are pivotal processes for prog-
nosis. Matrix metalloproteinases (MMPs) are produced by
inﬂammatory cells and tumor cells and are key players in
the degradation of the extracellular matrix and basement
membranes; thus, they are important in tumor invasion.
Gelatinases (MMP-2 and MMP-9), in particular, are prog-
nostic factors in many solid tumors, and their expression
is regulated by NF-κB activation. The clinical application of
an MMP inhibitor aimed at antimetastasis is expected [23].
Recent observations suggest that IKKβ/NF-κBa c t i v a t i o n
controls the development of liver metastasis through IL-6
expression, which is associated with tumor cell proliferation
and angiogenesis [24].
ItislikelythatNF-κBacti vationismostcriticalincanc ers
in which inﬂammation acts as a tumor promoter, but a more
general role for NF-κB remains to be established for the
inﬂammation mediated by its activation in cancers that are
not associated with inﬂammation.
3.3. NF-κB Activation and HCC. In clinical cases, constitu-
tive NF-κB activation has been frequently observed in tumor
tissuesratherthaninnontumortissues[25].Highexpression
of IKKα and IKKβ, which are critical kinases for NF-κB
activation, is necessary to produce the malignant properties
of liver cancer [26].
Although IKKβ-deﬁcient mice die at mid-gestation from
uncontrolled liver apoptosis [27], the IKKβ deﬁciency in the
hepatocytes does not inﬂuence their function and growth
[28]. However, following an injection of concanavalin A
(ConA), liver damage becomes worse in IKKβ hepatocyte-
speciﬁc IKKβ knockout mice, and TNFα,w h i c hc a u s e s
ConA expression on the T cell surface, is responsible for
the apoptotic action. This result suggests that IKKβ/NF-κB
activation of hepatocytes is important for the survival of
TNFα-mediated acute hepatitis and that inactivating NF-κB
may injure hepatocytes [28].
The roles of IKKβ in carcinogenesis have been examined
using diethylnitrosamine (DEN) as a chemical carcinogen.
DEN does not require any assistance from inﬂammation-
inducing tumor promoters if it is given to 2-week-old
male mice. An increase in hepatocyte death coincident
with an increase in reactive oxygen species (ROS) was
observed in knockout mice when the acute reaction was
analyzed following chemical carcinogen administration.
Furthermore, cell death was accompanied by inﬂammation,
and elevated hepatocyte death enhanced compensatory
proliferation due to the strong regenerative capacity of the
liver [29].
Decreased NF-κB activity and elevated JNK activity
promote TNF-α-induced cell death [30]. Accordingly, hep-
atocyte IKKβ ablation results in higher DEN-induced JNK
activity and increased cell death. Enhanced JNK activation
in the absence of IKKβ is dependent on ROS accumulation.
Interestingly, a reduction in ROS production by the antiox-
idant BHA controls liver cell death and proliferation and
reduces carcinogenesis [29].
Compensatory proliferation depends on the production
of factors such as TNF-α, IL-6, and hepatocyte growth
factor by nonparenchymal cells [31], and NF-κBa c t i v a t i o n
is important for producing these cytokines. Accordingly,
hepatocytes and blood cells, including Kupﬀer cells, which
are liver macrophages, were used in a carcinogenesis model
of IKKβ knockout mice, and the occurrence of HCC was
reduced. These results suggest that IKK/NF-κBa c t i v a t i o ni n
myeloid cells is important for producing liver growth factors
[29].
In fact, DEN-induced hepatocarcinogenesis has been
examined in IL-6 knockout mice and wild-type controls,
and a marked reduction in HCC incidence was seen in IL-6
knockout mice. Interestingly, gender disparity is observed in
mice given DEN, and ablation of IL-6 abolishes this gender
diﬀerence [32].
Recently, IKKβ deletion was observed to accelerate
HCC development and enhance tumor cell proliferation.
These eﬀects of IKKβ were correlated with increased ROS
accumulation, which led to JNK and STAT3 activation.
Accordingly, hepatocyte-speciﬁc STAT3 ablation prevents
HCC development. These results suggest that the negative
crosstalk between IKKβ and STAT3 is a critical regulator in
HCC development [33].
The IKK subunit NEMO/IKKγ is essential for activating
the NF-κB transcription factor, which regulates cellular
responses to inﬂammation. Hepatocyte-speciﬁc ablation of
NEMO causes the spontaneous development of HCC in
mice. Tumor development is preceded by chronic liver
disease such as NASH. These results reveal that NEMO-
mediated NF-κB activation in hepatocytes plays an essential
physiological role to prevent the spontaneous development
of NASH and HCC [34]. However, viral-induced activation
of IRF3 and IRF7 depends on NEMO, suggesting that
NEMO acts as an adaptor protein allowing RIG-I to
activate not only NF-κB, but also IRF signaling pathways.
Ablation of NEMO in the liver may inﬂuence the IRF
pathway [35].4 Gastroenterology Research and Practice
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3.4.NF-κBandTherapeuticTargetforHCC. ApplyingNF-κB
inhibitors for use as anticancer agents is expected. Through
an antiapoptosis eﬀect of NF-κB, the inhibition leads cells
to apoptosis. Furthermore, constitutive NF-κBa c t i v a t i o n
is observed in many cancer cells, and connection with a
malignancy of the cancer is assumed. IKKs or IκBs are now
the main targets of NF-κB inhibitors. Many researchers have
discovered various inhibitors that attenuate IKKα,I K K β,
IKKγ,o rI κBα,a n ds o m ea r ee ﬀective in animal models.
In our group, NEMO-binding domain peptide (NBD), one
of the inhibitors of IKKβ, has shown chemopreventive
eﬀects in a mouse colitis model [36]. Discovering drugs
that target these molecules appears to be attracting greater
attention, and the development of speciﬁc IKKβ inhibitors
has progressed rapidly. Several novel, small-molecule IKKβ
inhibitors have demonstrated anti-inﬂammatory activity,
and the advancement of IKKβ inhibitors into clinical devel-
opment is anticipated in the near future [37].
4. JNK andHCC
4.1. JNK Signaling Pathway. The c-Jun NH2-terminal kinase
(JNK) belongs to a family of mitogen-activated kinases
(MAPKs), together with extracellular regulated kinases
(ERKs) and p38. The JNK subgroup of MAPKs is encoded
by three loci; Jnk1 and Jnk2 are ubiquitously expressed,
and Jnk3 is expressed primarily in heart, testis, and brain
[38–40]. JNKs are activated by stress signals and proin-
ﬂammatory stimuli, and their activity increases following
phosphorylation by the MAPK kinases, MKK4, and MKK7
[41]( Figure 2).
Immunoblot analyses suggest that a 46-kDa molecule
represents JNK1 and a 54-kDa molecule represents JNK2.
However, a recent analysis revealed that the 46- and 54-
kDa molecules represent two isoforms of JNK1 and JNK2,
whereas the 46-kDa JNK1 and 54-kDa JNK2 are dominantly
expressed in most cell and tissue types [42]. Activated JNKs
phosphorylate c-Jun, JunD, ATF, and other transcriptional
factors,whichareinvolvedintheformationandactivationof
the AP-1 complex[43]. In addition, JNKs also phosphorylate
other proteins that induce apoptosis, cell proliferation, or
transformation, depending on the cell type and stimuli [44].
Using gene knockout mice, it has been shown that JNKs
are involved in many processes, including liver inﬂammation
and proliferation, neuronal apoptosis, T-cell activation, and
insulin resistance [45–49].
4.2. JNK Activation and Liver Disease. In the liver, activating
JNK was thought to be important for proliferation and
apoptosis. In a knockout-mice analysis, JNK1 was associated
with increased apoptosis in ConA-induced acute hepatitis
[28].Acetaminophen-inducedliverinjuryisalsoJNKdepen-
dent [50, 51]. Furthermore, mice lacking both JNK1 and 2
expression in hepatocytes exhibit the same degree of injury
in the development of hepatitis as control mice do, whereas
mice without JNK1/2 in the hematopoietic compartment
exhibitaprofounddefectinhepatitis thatisassociatedwitha
markedly reduced expression of TNF-α. It is suggested that a
role for JNK in the development of hepatitis, but identiﬁed
hematopoietic cells as the site of the essential function of
JNK [52]. JNK plays a pivotal role in the development of
metabolic syndrome including NAFLD [48, 53]. Hepatic
steatosis, inﬂammation, and ﬁbrosis have been examined
in mice fed a choline-deﬁcient L-amino-acid-deﬁned diet.
The results showed less hepatic inﬂammation and less liver
ﬁbrosis despite a similar level of hepatic steatosis in JNK1-
deﬁcient mice compared with wild type, suggesting that
JNK1 may be associated with the induction of diet-induced
steatohepatitis and liver ﬁbrosis [54].
4.3. JNK and Carcinogenesis. Tong et al. reported that JNK1
knockout mice spontaneously develop intestinal tumors,
suggesting a role for JNK1 in suppressing intestinal tumor
formation [55]. In contrast, mice lacking JNK1 were much
less susceptible to N-methyl-N-nitrosourea-induced gastric
carcinogenesis, which was correlated with decreased tumor
initiation and diminished cell proliferation [56]. These
ﬁndings suggest that the JNKs have tumor-promoting orGastroenterology Research and Practice 5
tumor-suppressing functions, depending on the cell type or
organ.
Tumor initiation indicates cellular immortality, which
occurs due to a DNA mutation, and the relationship with
the JNK activation is considered important. The presence
of mutated ras genes in 30% of all human cancers suggests
an important contribution to the development of human
cancers. Overexpression of mutated ras genes causes trans-
formation of a variety of rodent ﬁbroblast and epithelial
cell lines. Ras causes activation of a Raf-independent MAPK
cascade,whichleadstoJNKactivation[57],andinhibitionof
JNK activation also inhibits Ras transformation in NIH3T3
cells [58]. JNK1-dependent c-Myc and p21 are responsible
for the diminished checkpoint function in tumorigenic
hepatocytes [59].
JNK function is critical in the carcinogenic promotion
and progression stages, as JNK phosphorylates a variety of
genes associated with carcinogenesis. The promotion stage is
the proliferative stage of the cell, which becomes immortal,
andproliferation,anti-apoptosis,angiogenesis,invasion,and
metastasis are important [14].
Growth factors activate receptor tyrosine kinases, and
phosphorylated receptors transmit the signals through JNKs
[60]. There is also participation in the transcriptional regu-
lation of growth factors such as EGF through JNK activation
[61]. Numerous studies have considered the proliferative
eﬀect following JNK activation. For example, in a liver
regeneration mouse model, the number of Ki67-positive
proliferating hepatocytes in Jnk1−/− mice was reduced by
80% compared with that in controls at 48 hours after a
partial hepatectomy [59]. In an HCC model induced by
DEN, several important genes associated with proliferation
such as PCNA, cyclin D, and CDKs increased [4].
The expression of several angiogenic factors is also
regulatedbyJNK.Vascularendothelialgrowthfactor(VEGF)
promotes proliferation and migration of endothelium cells.
VEGF expression is also controlled by JNK activation [62].
Chemokinessuchasinterleukin(IL)-8arefactorscontrolling
leukocytes at the time of inﬂammation, but they function as
blood vessel growth factors in tumor tissue [63, 64].
4.4. JNK Activation and HCC. JNKs are protein kinases,
and many molecules are phosphorylated by JNKs. Approx-
imately, 70% of HCC tissues, but not background tissues,
show positive immunostaining for phosphorylated JNK,
suggesting that JNK is frequently active in human HCC [65].
In vitro studies suggest that several HBV and HCV proteins
are common etiologic pathogens for HCC-activated JNK in
cancer cells [66].
In addition to the clinical samples and in vitro studies,
JNK activation has been critically important in in vivo
mouse models. In hepatocyte-speciﬁc Ikkβ-deﬁcient mice,
DEN-induced liver cancer increased and JNK activation was
elevated simultaneously [29]. To determine the role of JNK
in these models, JNK1-deﬁcient mice were interbred with
Ikkβ-deﬁcient mice, and the results showed that JNK1 is a
critical factor for the increased incidence of HCC in Ikkβ-
deﬁcient mice [4]. Additionally, to determine the role of
JNK1 in DEN-induced hepatocarcinogenesis, wild-type and
Jnk1-deﬁcient mice were injected with DEN. All mice given
DEN developed typical HCCs, but the number of detectable
HCCs was reduced ﬁvefold by the JNK1 deﬁciency. Thus,
JNK1 is required for eﬃcient HCC induction in response to
DEN administration [4].
The downstream molecules phosphorylated by JNK
have been extensively investigated. Originally, JNKs were
identiﬁed as protein kinases that phosphorylated c-Jun on
serine residues [67]. c-Jun is a well-characterized oncogene,
especially in liver [68], and its phosphorylation by JNK
may be relevant in HCC development. The AP-1 tran-
scription factors, c-Jun and c-Fos, are composed of homo-
and heterodimers with basic region-leucine zipper proteins
belonging to the Jun (c-Jun, JunB, and JunD) and Fos (c-Fos,
FosB, Fra-1, and Fra-2) subfamilies, all of which recognize
the AP-1 binding site or TPA-response element in the regu-
latory region of AP-1 target genes [69]. Liver carcinogenesis
induced by DEN is dramatically reduced in mice lacking c-
Jun in hepatocytes. A putative mechanism accounting for the
reduced tumorigenic eﬀect was prevention of apoptosis by
c-Jun, and the prevention of apoptosis was associated with
p53 [68].
The tumorigenic eﬀect of JNK1 in the liver is mediated
through positive gene regulation or by cell proliferation
molecules such as cyclins and CDKs and metastatic factors
such as MMPs, VEGF, and others [4].
Based on an NF-κB and JNK study in an animal
hepatocarcinogenesis model, regulation of ROS-mediated
JNK activation is critical for developing cancer. Recent
studies have revealed that ROS production accompanies
many signaling events, including receptor signaling, and that
ROS play critical roles in determining cell fate as second
messengers and modifying various signaling molecules.
Sustained JNK activation is induced by ROS by activating
upstream MEKKs or inhibiting MKPs [70–72]. In fact,
enhanced JNK activation in IKKβ-deﬁcient mice has been
assessed. Hepatocyte-speciﬁc Ikkβ-knockout mice and Jnk1-
knockout mice were inter-bred and treated with DEN at
15 days of age. Double-knockout mice developed three-
fold fewer tumors compared with hepatocyte-speciﬁc Ikkβ-
knockout mice, and a similar decrease was found in maximal
tumor diameters. These results suggest that increased ROS
and ROS-mediated JNK activation is a critical regulator for
HCC development (Figure 3). Viral proteins including the
HBV X and HCV core proteins are capable of inducing ROS
accumulation in hepatocytes [73].
TAK1 is one of the MEKKs that activate both the NF-κB
and JNK pathways. Hepatocyte-speciﬁc Tak1-deﬁcient mice
display spontaneous hepatocyte death, compensatory pro-
liferation, inﬂammatory cell inﬁltration, and perisinusoidal
ﬁbrosis at the age of 1 month. Older mice develop multiple
cancer nodules characterized by increased expression of fetal
liver genes including alpha-fetoprotein. Cultures of primary
hepatocytes deﬁcient in Tak1 exhibit spontaneous cell death,
which is further increased in response to TNF-α. These
results indicate that TAK1 is an essential component of
cellular homeostasis in the liver [74].6 Gastroenterology Research and Practice
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4.5. JNK1 and Therapeutic Target for HCC. The ﬁndings
implicating a pivotal contribution of JNK in HCC develop-
ment suggest the use of a JNK inhibitor for treating HCC.
The most commonly used JNK inhibitor is SP600125, which
showshigheﬃcacyinblockingJNKkinaseactivity.Inanimal
models, this compound is eﬀective against acute hepatitis
inducedbyacetaminophenorLPS/GalN[51,75].Inamouse
model, the cell-permeable JIP peptide, which interferes with
the interaction between JIP and JNK to inhibit JNK activity,
suppresses chemically induced HCC [59].
5. HCCandTLRs
5.1. TLR Signaling. Innate immunity represents the ﬁrst line
of protection against microbial pathogens and is mediated
by macrophages and dendritic cells. Although it was initially
suggested to be a nonspeciﬁc response, innate immunity
discriminates a variety of pathogens through the function
of pattern-recognition receptors (PRRs) such as TLRs.
These receptors recognize microbial components known
as pathogen-associated molecular patterns [76]. Thirteen
mammalian TLRs have been described; 10 are expressed
in humans, and each is responsible for recognizing distinct
bacteria, virus, and fungi microbial structures. The two most
eagerly studied are TLR2 and TLR4, the PRRs for gram-
negative and gram-positive bacterial products, respectively.
TLR4 is also the major receptor recognizing endogenous
ligands released from damaged or dying cells. TLRs are
characterized by two conserved regions: the extracellular
leucine-rich region and the cytoplasmic Toll/IL-1 receptor
(TIR) domain. A detailed characterization of the TLRs is
described in other chapters.
TLRs share the initial common activation pathway
mediated by the TIR domain. After receptor activation,
two signaling pathways mainly exist; one is through the
adapter protein myeloid diﬀerentiation factor 88 (MyD88),
and the other is not. All superfamily receptors, with the
exception of TLR3, use MyD88 to initiate signaling. In some
cases, MyD88 acts in concert with other adaptors, such
as MAL/TIRAP, in the response triggered by stimulating
TLR4, TLR1/2, and TLR2/6. In contrast, TLR3-mediated
signaling requires only the TRIF adaptor molecule, which
is also recruited by TLR4 in association with the other
adaptor, TRAM [77]. In the MyD88-dependent pathway,
MyD88 is associated with IRAK4, IRAK1, and/or IRAK2.
IRAK4 in turn phosphorylates IRAK1, and IRAK2 promotes
their association with TRAF6, which serves as a platform to
recruit TAK1 kinase. Once activated, TAK1 activates the IKK
complex and eventually activates NF-κB and JNK. The IRF7
transcription factor is also activated downstream of TLRs 7,
8, and 9, leading to its translocation into the nucleus and
to activation of IFN and IFN-inducible genes. TLR3 and
TLR4 both signal through the TRIF adaptor, which interacts
with TRAF3 to activate the nonclassical IKKs and the IKK,
resulting in the dimerization and activation of IRF3, which
then translocates to the nucleus activating the transcription
of IFN and IFN-induced genes [78].
5.2. TLR Signal and Liver Disease. T h el i v e rm a yb ee x p o s e d
to bacteria from the intestine via the portal vein, leading to
an uncontrolled innate immune system that may result in
inﬂammatory liver disorders [79]. Many factors are capable
of activating TLRs in the liver. Among them, HBV, HCV,
alcoholic liver disease, and NASH are important etiologies
for HCC.
The TLR ligands TLR4 and 9 inhibit viral replication
in HBV-transgenic mice [80]. In the absence of HBeAg,
HBV replication is associated with upregulation of the
TLR2 pathway, leading to increased TNFα production,
demonstrating a potentially important interaction between
HBV and the innate immune response [81].
HCV can activate innate immune systems to produce
inﬂammation. The HCV core and NS3 proteins activate
TLR2 on monocytes to induce cytokines in a NF-κB- andGastroenterology Research and Practice 7
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JNK-dependent manner [82]. The NS3 protein interacts
directly with TBK1, resulting in decreased TBK1-IRF3 inter-
action and inhibition of IRF3 and IFN transcription. The
NS3 protein also impedes both IRF3 and NF-κBa c t i v a t i o n
by reducing functional TRIF abundance [83]. Many other in
vitro studies have been reported, but the in vivo condition is
still unclear.
Excessive alcohol intake is associated with increased
intestinal permeability and elevated endotoxin levels [84].
LPS activates TLR4 on Kupﬀer cells and increases proinﬂam-
matory cytokine production. Antibiotic treatment reduces
the sensitivity of alcoholic liver disease [85, 86].
Intestinal bacteria seem to be important in NASH
pathogenesis.InNASH,ob/obmiceexhibitincreasedhepatic
sensitivity to LPS and developed steatohepatitis [87]. In a
methionine/choline-deﬁcient NASH model, TLR4-deﬁcient,
butnot TLR2-deﬁcientmice, exhibited lessintrahepatic lipid
accumulation [88].
5.3.TLRSignalandHCC. Allofthediseasesdescribedabove
are associated with the development of HCC. Therefore, it
seems clear that TLRs are involved in the development of
HCC. It is very important to analyze which cell types are
involved in the process to understand liver tumorigenesis.
Kupﬀer cells may be the major cells expressing TLRs in
liver. Kupﬀer cells are resident liver macrophages and express
most major TLRs [89]. In contrast, hepatocytes, the liver
parenchymal cells, show weak TLR 2 and TLR4 expression
and less response against their ligands [90, 91]. TLR2
expression in hepatocytes is upregulated by LPS, TNF, and
others, suggesting that hepatocytes become more sensitive in
the inﬂammatory condition [92].
Mice deﬁcient in TLR4 and MyD88, but not TLR2, have
a marked decrease in the incidence, size, and number of
chemically induced (DEN) liver cancer tumors, indicating a
strong contribution of TLR signaling to hepatocarcinogene-
sis [79]. It is assumed that dying hepatocytes following DEN
m a ya c t i v a t em y e l o i dc e l l ss u c ha sK u p ﬀer cells via TLRs
and induce proinﬂammatory cytokines and hepatomitogens,
which enhance the development of HCC [93].
MyD88 is an adapter molecule for TLRs necessary for
NF-κB, and MyD88 ablation strongly suppresses DEN-
induced hepatocarcinogenesis [32]. IL-6 induction and liver
injury are dependent on signaling via MyD88. Collectively,
TLR4-MyD88 signaling appears to be essential for hepato-
carcinogenesis.
6. Conclusion
Participation of the IKKβ/NF-κB and JNK signaling path-
ways in carcinogenesis diﬀers among organs, cells, and
models. The crosstalk between an inﬂammatory cell and
a neoplastic cell, which is instigated by the activation of
NF-κB, is critical for tumor organization (Figure 4). JNKs8 Gastroenterology Research and Practice
also regulate cell proliferation and apoptosis, making them
the main tumor-promoting protein kinases. TLRs play
roles in cytokine and hepatomitogen expression mainly in
myeloid cells and may promote liver tumorigenesis. These
observations suggest that a better understanding of these
signaling pathways in the liver will help us understand
the mechanism of hepatocarcinogenesis and provide a new
therapeutic target for HCC.
References
[ 1 ]F .X .B o s c h ,J .R i b e s ,M .D ´ ıaz, and R. Cl´ eries, “Primary liver
cancer: worldwide incidence and trends,” Gastroenterology,
vol. 127, pp. S5–S16, 2004.
[2] K. Koike, T. Tsutsumi, H. Fujie, Y. Shintani, and K. Moriya,
“Molecular mechanism of viral hepatocarcinogenesis,” Oncol-
ogy, vol. 62, no. 1, pp. 29–37, 2002.
[3] N. Fausto, “Mouse liver tumorigenesis: models, mechanisms,
and relevance to human disease,” Seminars in Liver Disease,
vol. 19, no. 3, pp. 243–252, 1999.
[4] T. Sakurai, S. Maeda, L. Chang, and M. Karin, “Loss of
hepatic NF-κB activity enhances chemical hepatocarcinogen-
esis through sustained c-Jun N-terminal kinase 1 activation,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 103, no. 28, pp. 10544–10551, 2006.
[5] N. Kato, H. Yoshida, S. Kioko Ono-Nita et al., “Activation of
intracellular signaling by hepatitis B and C viruses: C-viral
core is the most potent signal inducer,” Hepatology, vol. 32,
no. 2, pp. 405–412, 2000.
[6] S. H. Caldwell and D. M. Crespo, “The spectrum expanded:
cryptogenic cirrhosis and the natural history of non-alcoholic
fatty liver disease,” J o u r n a lo fH e p a t o l o g y ,v o l .4 0 ,n o .4 ,p p .
578–584, 2004.
[7] E. E. Calle and R. Kaaks, “Overweight, obesity and cancer:
epidemiological evidence and proposed mechanisms,” Nature
Reviews Cancer, vol. 4, no. 8, pp. 579–591, 2004.
[8] E.J.Park,J.H.Lee,G.-Y.Yuetal.,“Dietaryandgeneticobesity
promote liver inﬂammation and tumorigenesis by enhancing
IL-6 and TNF expression,” Cell, vol. 140, no. 2, pp. 197–208,
2010.
[9] E. Dejardin, N. M. Droin, M. Delhase et al., “The
lymphotoxin-β receptor induces diﬀerent patterns of gene
expression via two NF-κBp a t h w a y s , ”Immunity, vol. 17, no.
4, pp. 525–535, 2002.
[10] S. Ghosh and M. Karin, “Missing pieces in the NF-κB puzzle,”
Cell, vol. 109, no. 2, pp. S81–S96, 2002.
[11] F. Aslund and J. Beckwith, “The thioredoxin superfamily:
redundancy, speciﬁcity, and gray-area genomics,” Journal of
Bacteriology, vol. 181, no. 5, pp. 1375–1379, 1999.
[12] M.Karin,Y.Cao,F.R.Greten,andZ.-W.Li,“NF-κBincanc e r:
from innocent bystander to major culprit,” Nature Reviews
Cancer, vol. 2, no. 4, pp. 301–310, 2002.
[13] N. Kabrun and P. J. Enrietto, “The Rel family of proteins in
oncogenesis and diﬀerentiation,” Seminars in Cancer Biology,
vol. 5, no. 2, pp. 103–112, 1994.
[14] D. Hanahan and R. A. Weinberg, “The hallmarks of cancer,”
Cell, vol. 100, no. 1, pp. 57–70, 2000.
[15] P. W. Szlosarek and F. R. Balkwill, “Tumour necrosis factor α:
a potential target for the therapy of solid tumours,” The Lancet
Oncology, vol. 4, no. 9, pp. 565–573, 2003.
[16] D .C.G u ttridg e,C.A lbanese,J .Y .R e u the r ,R.G.P est ell,andA.
S. Baldwin Jr., “NF-κB controls cell growth and diﬀerentiation
through transcriptional regulation of cyclin D1,” Molecular
and Cellular Biology, vol. 19, no. 8, pp. 5785–5799, 1999.
[17] K. S. Koch, S. Maeda, G. He, M. Karin, and H. L. Leﬀert,
“Targeted deletion of hepatocyte Ikkβ confers growth advan-
tages,” Biochemical and Biophysical Research Communications,
vol. 380, no. 2, pp. 349–354, 2009.
[18] M. Karin and A. Lin, “NF-κB at the crossroads of life and
death,” Nature Immunology, vol. 3, no. 3, pp. 221–227, 2002.
[19] S. M¨ uerk¨ oster, A. Arlt, B. Sipos et al., “Increased expression
of the E3-ubiquitin ligase receptor subunit βTRCP1 relates to
constitutive nuclear factor-κB activation and chemoresistance
in pancreatic carcinoma cells,” Cancer Research, vol. 65, no. 4,
pp. 1316–1324, 2005.
[20] Q. Cheng, H. H. Lee, Y. Li, T. P. Parks, and G. Cheng,
“Upregulation of Bcl-x an Bﬂ-1 as a potential mechanism of
chemoresistance, which can be overcome by NF-κB inhibi-
tion,” Oncogene, vol. 19, no. 42, pp. 4936–4940, 2000.
[21] A. B. Kunnumakkara, S. Guha, S. Krishnan, P. Diagaradjane,
J. Gelovani, and B. B. Aggarwal, “Curcumin potentiates
antitumor activity of gemcitabine in an orthotopic model
of pancreatic cancer through suppression of proliferation,
angiogenesis, and inhibition of nuclear factor-κB-regulated
gene products,” Cancer Research, vol. 67, no. 8, pp. 3853–3861,
2007.
[22] K. Sakamoto, S. Maeda, Y. Hikiba et al., “Constitutive
NF-κB activation in colorectal carcinoma plays a key role
in angiogenesis, promoting tumor growth,” Clinical Cancer
Research, vol. 15, no. 7, pp. 2248–2258, 2009.
[23] M. Egeblad and Z. Werb, “New functions for the matrix
metalloproteinases in cancer progression,” Nature Reviews
Cancer, vol. 2, no. 3, pp. 161–174, 2002.
[24] S. Maeda, Y. Hikiba, K. Sakamoto et al., “Ikappa B
kinaseβ/nuclearfactor-κBactivationcontrolsthedevelopment
of liver metastasis by way of interleukin-6 expression,” Hepa-
tology, vol. 50, no. 6, pp. 1851–1860, 2009.
[25] D.-I.Tai,S.-L.Tsai,Y.-H.Changetal.,“Constitutiveactivation
of nuclear factor κB in hepatocellular carcinoma,” Cancer, vol.
89, no. 11, pp. 2274–2281, 2000.
[26] R. Jiang, Y. Xia, J. Li et al., “High expression levels of IKKα
and IKKβ are necessary for the malignant properties of liver
cancer,” International Journal of Cancer, vol. 126, no. 5, pp.
1263–1274, 2010.
[27] Z.-W. Li, W. Chu, Y. Hu et al., “The IKKβ subunit of IκB
kinase (IKK) is essential for nuclear factor κB activation and
prevention of apoptosis,” Journal of Experimental Medicine,
vol. 189, no. 11, pp. 1839–1845, 1999.
[28] S. Maeda, L. Chang, Z.-W. Li, J.-L. Luo, H. Leﬀert, and M.
Karin, “IKKβ is required for prevention of apoptosis mediated
bycell-boundbutnotbycirculatingTNFα,” Immunity,vol.19,
no. 5, pp. 725–737, 2003.
[29] S. Maeda, H. Kamata, J.-L. Luo, H. Leﬀe r t ,a n dM .K a r i n ,
“IKKβ couples hepatocyte death to cytokine-driven compen-
satory proliferation that promotes chemical hepatocarcino-
genesis,” Cell, vol. 121, no. 7, pp. 977–990, 2005.
[30] G. Tang, Y. Minemoto, B. Dibling et al., “Inhibition of JNK
activation through NF-κB target genes,” Nature, vol. 414, no.
6861, pp. 313–317, 2001.
[31] N. Fausto, “Liver regeneration,” Journal of Hepatology, vol. 32,
no. 1, pp. 19–31, 2000.
[32] W. E. Naugler, T. Sakurai, S. Kim et al., “Gender disparity in
liver cancer due to sex diﬀerences in MyD88-dependent IL-6
production,” Science, vol. 317, no. 5834, pp. 121–124, 2007.Gastroenterology Research and Practice 9
[33] G. He, G.-Y. Yu, V. Temkin et al., “Hepatocyte IKKβ/NF-
κB inhibits tumor promotion and progression by preventing
oxidative stress-driven STAT3 activation,” Cancer Cell, vol. 17,
no. 3, pp. 286–297, 2010.
[34] T. Luedde, N. Beraza, V. Kotsikoris et al., “Deletion of
NEMO/IKKγ in liver parenchymal cells causes steatohepatitis
and hepatocellular carcinoma,” Cancer Cell,v o l .1 1 ,n o .2 ,p p .
119–132, 2007.
[35] T. Zhao, L. Yang, Q. Sun et al., “The NEMO adaptor
bridges the nuclear factor-κB and interferon regulatory factor
signaling pathways,” Nature Immunology, vol. 8, no. 6, pp.
592–600, 2007.
[36] Y. Hayakawa, S. Maeda, H. Nakagawa et al., “Eﬀectiveness of
IκB kinase inhibitors in murine colitis-associated tumorigen-
esis,” Journal of Gastroenterology, vol. 44, no. 9, pp. 935–943,
2009.
[37] M. Karin, Y. Yamamoto, and Q. M. Wang, “The IKK NF-
κB system: a treasure trove for drug development,” Nature
Reviews Drug Discovery, vol. 3, no. 1, pp. 17–26, 2004.
[38] B. D´ erijard, M. Hibi, I.-H. Wu et al., “JNK1: a protein
kinase stimulated by UV light and Ha-Ras that binds and
phosphorylates the c-Jun activation domain,” Cell, vol. 76, no.
6, pp. 1025–1037, 1994.
[39] T. Kallunki, B. Su, I. Tsigelny et al., “JNK2 contains a
speciﬁcity-determining region responsible for eﬃcient c-Jun
binding and phosphorylation,” Genes and Development, vol. 8,
no. 24, pp. 2996–3007, 1994.
[40] A. A. Mohit, J. H. Martin, and C. A. Miller, “p49(3F12) kinase:
a novel MAP kinase expressed in a subset of neurons in the
human nervous system,” Neuron, vol. 14, no. 1, pp. 67–78,
1995.
[41] X. Wang, A. Destrument, and C. Tournier, “Physiological
roles of MKK4 and MKK7: insights from animal models,”
Biochimica et Biophysica Acta, vol. 1773, no. 8, pp. 1349–1357,
2007.
[42] S. Gupta, T. Barrett, A. J. Whitmarsh et al., “Selective
interaction of JNK protein kinase isoforms with transcription
factors,” The EMBO Journal, vol. 15, no. 11, pp. 2760–2770,
1996.
[43] E. Shaulian and M. Karin, “AP-1 as a regulator of cell life and
death,” Nature Cell Biology, vol. 4, no. 5, pp. E131–E136, 2002.
[44] C. R. Weston and R. J. Davis, “The JNK signal transduction
pathway,” Current Opinion in Genetics and Development, vol.
12, no. 1, pp. 14–21, 2002.
[45] K. Sabapathy, Y. Hu, T. Kallunki et al., “JNK2 is required for
eﬃcient T-cell activation and apoptosis but not for normal
lymphocyte development,” Current Biology,v o l .9 ,n o .3 ,p p .
116–125, 1999.
[46] K. Sabapathy and E. F. Wagner, “JNK2: a negative regulator of
cellular proliferation,” Cell Cycle, vol. 3, no. 12, pp. 1520–1523,
2004.
[47] C.-Y. Kuan, D. D. Yang, D. R. Samanta Roy, R. J. Davis, P.
Rakic, and R. A. Flavell, “The Jnk1 and Jnk2 protein kinases
are required for regional speciﬁc apoptosis during early brain
development,” Neuron, vol. 22, no. 4, pp. 667–676, 1999.
[48] J. Hirosumi, G. Tuncman, L. Chang et al., “A central, role for
JNK in obesity and insulin resistance,” Nature, vol. 420, no.
6913, pp. 333–336, 2002.
[49] C.Tournier,P.Hess,D.D.Yangetal.,“RequirementofJNKfor
stress-induced activation of the cytochrome c-mediated death
pathway,” Science, vol. 288, no. 5467, pp. 870–874, 2000.
[50] N. Hanawa, M. Shinohara, B. Saberi, W. A. Gaarde, D. Han,
and N. Kaplowitz, “Role of JNK translocation to mitochon-
dria leading to inhibition of mitochondria bioenergetics in
acetaminophen-induced liver injury,” Journal of Biological
Chemistry, vol. 283, no. 20, pp. 13565–13577, 2008.
[51] H.Nakagawa,S.Maeda,Y.Hikibaetal.,“Deletionofapoptosis
signal-regulating kinase 1 attenuates acetaminophen-induced
liver injury by inhibiting c-Jun N-terminal kinase activation,”
Gastroenterology, vol. 135, no. 4, pp. 1311–1321, 2008.
[52] M. Das, G. Sabio, F. Jiang, M. Rinc´ on, R. A. Flavell, and R. J.
Davis, “Induction of hepatitis by JNK-mediated expression of
TNF-α,” Cell, vol. 136, no. 2, pp. 249–260, 2009.
[53] V. T. Samuel, Z.-X. Liu, X. Qu et al., “Mechanism of hepatic
insulin resistance in non-alcoholic fatty liver disease,” Journal
of Biological Chemistry, vol. 279, no. 31, pp. 32345–32353,
2004.
[54] Y. Kodama, T. Kisseleva, K. Iwaisako et al., “c-Jun N-terminal
kinase-1 from hematopoietic cells mediates progression from
hepatic steatosis to steatohepatitis and ﬁbrosis in mice,”
Gastroenterology, vol. 137, no. 4, pp. 1467–1477, 2009.
[55] C. Tong, Z. Yin, Z. Song et al., “c-Jun NH2-terminal kinase
1 plays a critical role in intestinal homeostasis and tumor
suppression,” American Journal of Pathology, vol. 171, no. 1,
pp. 297–303, 2007.
[56] W. Shibata, S. Maeda, Y. Hikiba et al., “c-Jun NH2-terminal
kinase 1 is a critical regulator for the development of gastric
cancer in mice,” Cancer Research, vol. 68, no. 13, pp. 5031–
5039, 2008.
[57] A.Minden,A.Lin,M.McMahonetal.,“Diﬀerentialactivation
of ERK and JNK mitogen-activated protein kinases by Raf-1
and MEKK,” Science, vol. 266, no. 5191, pp. 1719–1723, 1994.
[58] G.J.Clark,J.K.Westwick,andC.J.Der,“p120GAPmodulates
Ras activation of jun kinases and transformation,” Journal of
Biological Chemistry, vol. 272, no. 3, pp. 1677–1681, 1997.
[59] L. Hui, K. Zatloukal, H. Scheuch, E. Stepniak, and E. F.
Wagner, “Proliferation of human HCC cells and chemically
induced mouse liver cancers requires JNK1-dependent p21
downregulation,” Journal of Clinical Investigation, vol. 118, no.
12, pp. 3943–3953, 2008.
[ 6 0 ]F .B o s t ,R .M c K a y ,N .D e a n ,a n dD .M e r c o l a ,“ T h eJ U N
kinase/stress-activated protein kinase pathway is required for
epidermal growth factor stimulation of growth of human
A549 lung carcinoma cells,” Journal of Biological Chemistry,
vol. 272, no. 52, pp. 33422–33429, 1997.
[ 6 1 ]C .R .W e s t o n ,A .W o n g ,J .P .H a l l ,M .E .P .G o a d ,R .A .F l a v e l l ,
and R. J. Davis, “The c-Jun NH2-terminal kinase is essential
for epidermal growth factor expression during epidermal
morphogenesis,” Proceedings of the National Academy of
Sciences of the United States of America, vol. 101, no. 39, pp.
14114–14119, 2004.
[ 6 2 ]M .G u m a ,J .R i u s ,K .X .D u o n g - P o l k ,G .G .H a d d a d ,J .
D. Lindsey, and M. Karin, “Genetic and pharmacological
inhibition of JNK ameliorates hypoxia-induced retinopathy
through interference with VEGF expression,” Proceedings of
the National Academy of Sciences of the United States of
America, vol. 106, no. 21, pp. 8760–8765, 2009.
[63] R. M. Strieter, P. J. Polverini, D. A. Arenberg et al., “Role of C-
X-C chemokines as regulators of angiogenesis in lung cancer,”
Journal of Leukocyte Biology, vol. 57, no. 5, pp. 752–762, 1995.
[64] S. Yoshida, M. Ono, T. Shono et al., “Involvement of
interleukin-8, vascular endothelial growth factor, and basic
ﬁbroblast growth factor in tumor necrosis factor alpha-
dependent angiogenesis,” Molecular and Cellular Biology, vol.
17, no. 7, pp. 4015–4023, 1997.10 Gastroenterology Research and Practice
[65] Q. Chang, Y. Zhang, K. J. Beezhold et al., “Sustained JNK1
activation is associated with altered histone H3 methylations
in human liver cancer,” Journal of Hepatology, vol. 50, no. 2,
pp. 323–333, 2009.
[66] C. Tarn, S. Lee, Y. Hu, C. Ashendel, and O. M. Andrisani,
“Hepatitis B virus X protein diﬀerentially activates RAS-
RAF-MAPK and JNK pathways in X-transforming versus
non-transforming AML12 hepatocytes,” Journal of Biological
Chemistry, vol. 276, no. 37, pp. 34671–34680, 2001.
[67] M. Hibi, A. Lin, T. Smeal, A. Minden, and M. Karin, “Identi-
ﬁcation of an oncoprotein- and UV-responsive protein kinase
thatbindsandpotentiatesthec-Junactivationdomain,” Genes
and Development, vol. 7, no. 11, pp. 2135–2148, 1993.
[68] R. Eferl, R. Ricci, L. Kenner et al., “Liver tumor development:
c-Jun antagonizes the proapoptotic activity of p53,” Cell, vol.
112, no. 2, pp. 181–192, 2003.
[69] P. Angel and M. Karin, “The role of Jun, Fos and the AP-1
complex in cell-proliferation and transformation,” Biochimica
et Biophysica Acta, vol. 1072, no. 2-3, pp. 129–157, 1991.
[70] A. Matsuzawa and H. Ichijo, “Redox control of cell fate by
MAPkinase:physiologicalrolesofASK1-MAPkinasepathway
in stress signaling,” Biochimica et Biophysica Acta, vol. 1780,
no. 11, pp. 1325–1336, 2008.
[71] F. Chen, K. Beezhold, and V. Castranova, “JNK1, a potential
therapeutictargetforhepatocellularcarcinoma,” Biochimicaet
Biophysica Acta, vol. 1796, no. 2, pp. 242–251, 2009.
[ 7 2 ]H .K a m a t a ,S . - I .H o n d a ,S .M a e d a ,L .C h a n g ,H .H i r a t a ,a n d
M. Karin, “Reactive oxygen species promote TNFα-induced
death and sustained JNK activation by inhibiting MAP kinase
phosphatases,” Cell, vol. 120, no. 5, pp. 649–661, 2005.
[73] M. Okuda, K. Li, M. R. Beard et al., “Mitochondrial injury,
oxidative stress, and antioxidant gene expression are induced
by hepatitis C virus core protein,” Gastroenterology, vol. 122,
no. 2, pp. 366–375, 2002.
[74] S. Inokuchi, T. Aoyama, K. Miura et al., “Disruption of TAK1
in hepatocytes causes hepatic injury, inﬂammation, ﬁbrosis,
and carcinogenesis,” Proceedings of the National Academy of
SciencesoftheUnitedStatesofAmerica,vol.107,no.2,pp.844–
849, 2010.
[75] M. Takamura, Y. Matsuda, S. Yamagiwa et al., “An inhibitor of
c-Jun NH2-terminal kinase, SP600125, protects mice from d-
galactosamine/lipopolysaccharide-induced hepatic failure by
modulating BH3-only proteins,” Life Sciences, vol. 80, no. 14,
pp. 1335–1344, 2007.
[76] O. Takeuchi and S. Akira, “Toll-like receptors; their physi-
ological role and signal transduction system,” International
Immunopharmacology, vol. 1, no. 4, pp. 625–635, 2001.
[77] L. A. J. O’Neill and A. G. Bowie, “The family of ﬁve: TIR-
domain-containing adaptors in Toll-like receptor signalling,”
Nature Reviews Immunology, vol. 7, no. 5, pp. 353–364, 2007.
[78] S. Akira, S. Uematsu, and O. Takeuchi, “Pathogen recognition
and innate immunity,” Cell, vol. 124, no. 4, pp. 783–801, 2006.
[79] E. Seki and D. A. Brenner, “Toll-like receptors and adaptor
molecules in liver disease: update,” Hepatology, vol. 48, no. 1,
pp. 322–335, 2008.
[80] M. Isogawa, M. D. Robek, Y. Furuichi, and F. V. Chisari, “Toll-
like receptor signaling inhibits hepatitis B virus replication in
vivo,” Journal of Virology, vol. 79, no. 11, pp. 7269–7272, 2005.
[81] K. Visvanathan, N. A. Skinner, A. J. V. Thompson et al.,
“Regulation of Toll-like receptor-2 expression in chronic
hepatitis B by the precore protein,” Hepatology, vol. 45, no. 1,
pp. 102–110, 2007.
[82] A. Dolganiuc, S. Oak, K. Kodys et al., “Hepatitis C core and
nonstructural 3 proteins trigger toll-like receptor 2-mediated
pathways and inﬂammatory activation,” Gastroenterology, vol.
127, no. 5, pp. 1513–1524, 2004.
[83] K. Li, E. Foy, J. C. Ferreon et al., “Immune evasion by hepatitis
C virus NS3/4A protease-mediated cleavage of the Toll-like
receptor 3 adaptor protein TRIF,” Proceedings of the National
Academy of Sciences of the United States of America, vol. 102,
no. 8, pp. 2992–2997, 2005.
[84] I. Bjarnason, K. Ward, and T. J. Peters, “The leaky gut of
alcoholism: possible route of entry for toxic compounds,” The
Lancet, vol. 1, no. 8370, pp. 179–182, 1984.
[85] Y. Adachi, L. E. Moore, B. U. Bradford, W. Gao, and R. G.
Thurman, “Antibiotics prevent liver injury in rats following
long-term exposure to ethanol,” Gastroenterology, vol. 108, no.
1, pp. 218–224, 1995.
[ 8 6 ]T .U e s u g i ,M .F r o h ,G .E .A r t e e l ,B .U .B r a d f o r d ,a n dR .G .
Thurman, “Toll-like receptor 4 is involved in the mechanism
of early alcohol-induced liver injury in mice,” Hepatology, vol.
34, no. 1, pp. 101–108, 2001.
[87] S. Q. Yang, H. Z. Lin, M. D. Lane, M. Clemens, and A.
M. Diehl, “Obesity increases sensitivity to endotoxin liver
injury: implications for the pathogenesis of steatohepatitis,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 94, no. 6, pp. 2557–2562, 1997.
[ 8 8 ]C .A .R i v e r a ,P .A d e g b o y e g a ,N .v a nR o o i j e n ,A .T a g a l i c u d ,M .
Allman, and M. Wallace, “Toll-like receptor-4 signaling and
Kupﬀer cells play pivotal roles in the pathogenesis of non-
alcoholic steatohepatitis,” Journal of Hepatology, vol. 47, no. 4,
pp. 571–579, 2007.
[89] R. F. Schwabe, E. Seki, and D. A. Brenner, “Toll-Like receptor
signaling in the liver,” Gastroenterology, vol. 130, no. 6, pp.
1886–1900, 2006.
[90] T. Matsumura, T. Degawa, T. Takii et al., “TRAF6-NF-κB
pathway is essential for interleukin-1-induced TLR2 expres-
sion and its functional response to TLR2 ligand in murine
hepatocytes,” Immunology, vol. 109, no. 1, pp. 127–136, 2003.
[91] S.Liu,D.J.Gallo,A.M.Greenetal.,“Roleoftoll-likereceptors
in changes in gene expression and NF-κBa c t i v a t i o ni nm o u s e
hepatocytes stimulatedwithlipopolysaccharide,” Infection and
Immunity, vol. 70, no. 7, pp. 3433–3442, 2002.
[92] T. Matsumura, A. Ito, T. Takii, H. Hayashi, and K. Onozaki,
“Endotoxinandcytokineregulationoftoll-likereceptor(TLR)
2 and TLR4 gene expression in murine liver and hepatocytes,”
Journal of Interferon and Cytokine Research, vol. 20, no. 10, pp.
915–921, 2000.
[93] S. Maeda and M. Omata, “Inﬂammation and cancer: role of
nuclear factor-kappaB activation,” Cancer Science, vol. 99, no.
5, pp. 836–842, 2008.